1. P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS. (23rd June 2022) Authors: Vannucchi, A.; Pemmaraju, N.; Scott, B.; Savona, M.; Oh, S.; Palandri, F.; Al-Ali, H. K.; Sobas, M.; McMullin, M. F.; Gupta, V.; Yacoub, A.; Mesa, R.; Buckley, S.; Roman-Torres, K.; Verstovsek, S.; Harrison, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 958 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA. (23rd June 2022) Authors: Harrison, C.; Bose, P.; Mesa, R.; Gerds, A.; Oh, S.; Kiladjian, J.-J.; García-Gutierrez, V.; Vannucchi, A.; Scheid, C.; Sobas, M.; Verstovsek, S.; Buckley, S.; Roman-Torres, K.; Mascarenhas, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 959 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗